Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References +12% Growth drivers² Mature products³ 6.6 ■ 5.6 0.5 0.3 +35% 2.8 2.1 3.2 3.3 -4% Pharmaceuticals grew +12% in Q2 with growth drivers and launches showing strong momentum Pharmaceuticals net sales USD bn, % cc Launches1 Growth drivers showing strong momentum in Q2 vs. prior year ■ CosentyxⓇ and EntrestoⓇ together reached USD >2bn ZolgensmaⓇ up +48% YoY driven by geographic expansion llarisⓇ up +21% driven by Adult Onset Still Disease, Periodic Fever Syndrome New portfolio building foundation for future growth Q2 2020 Q2 2021 ■ +6% ■ Growth drivers and launches represent 51% of sales (up from 43% Q2 2020) CosentyxⓇ LCM progressing with regulatory milestones for pediatric portfolio LeqvioⓇ re-submitted in US – launch preparations on track 13.0 11.7 1.0 0.6 4.3 5.4 +29% 6.9 6.5' -10% H1 2020 H1 2021 LCM Lifecycle Management. All % growth relate to cc unless otherwise stated. 1. ZolgensmaⓇ, KesimptaⓇ, MayzentⓇ, BeovuⓇ, LuxturnaⓇ, LeqvioⓇ, EnerzairⓇ and AtecturaⓇ. 2. Cosentyx®, Entresto®, Xolair®, llaris®, XiidraⓇ and AimovigⓇ 3. All other brands. 19 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation